Work

A phase II randomised study to evaluate the antitumour activity of roginolisib, a novel non-ATP competitive and allosteric modulator inhibiting PI3Kδ, in patients with metastatic uveal melanoma (OCULE-01).

Year: 2025

Type: conference-abstract

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps9613

Authors: Paul D. Nathan, Anna Maria Di Giacomo, Josep M. Piulats, Giusy Di Conza, Tracey Hammett, Paramjit Kaur, Karen Tonge, Lars Anders van der Veen, Michael M. F. Lahn

Institutions: Mount Vernon Hospital, University of Siena, Network Italiano Per la Bioterapia Dei Tumori, Institut d'Investigació Biomédica de Bellvitge, iOnctura SA (Switzerland)

Language: English

Topic: Ocular Oncology and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410805201

Cites:

Cited by:

Related to: 10